[1] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-E386.
[2] 张玉双, 李晶.晚期非小细胞肺癌真实世界研究现状[J]. 中国全科医学, 2020, 23(21):2607-2614.
[3] SIEGEL R, NAISHADHAM D, JEMAL A.Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1):11-30.
[4] ALLEMANI C, WEIR H K, CARREIRA H, et al. Global surveillance of cancer survival 1995-2009:analysis of individual data for 25, 676, 887 patients from 279 population-based registries in 67 countries(CONCORD-2)[J]. Lancet, 2015, 385(9972):977-1010.
[5] 唐翠萍, 秦思, 伍万春, 等.Ⅲa期非小细胞肺癌新辅助化疗的疗效分析及应用价值[J]. 中国肺癌杂志, 2017, 20(2):100-106.
[6] ZHANG H, YANG W, YAN J, et al. Loss of profilin 2 contributes to enhanced epithelial-mesenchymal transition and metastasis of colorectal cancer[J]. Int J Oncol, 2018, 53(3):1118-1128.
[7] KIM M J, LEE Y S, HAN G Y, et al. Profilin 2 promotes migration, invasion, and stemness of HT29 human colorectal cancer stem cells[J]. Biosci Biotechnol Biochem, 2015, 79(9):1438-1446.
[8] 王蓉, 李大鹏, 冯军.参麦注射液联合化疗对晚期非小细胞肺癌患者T细胞亚群及细胞因子的影响[J]. 南京中医药大学学报, 2016, 32(2):125-128.
[9] 李静, 袁涛, 秦冬梅, 等.小分子酪氨酸激酶抑制剂治疗非小细胞肺癌的回顾性分析[J]. 中国药房, 2016, 27, 48(2):213-215.
[10] ENG L, HARðRDOTTíR H, SONG H, et al. Mortality of lung cancer as a second primary malignancy:a population-based cohort study[J]. Cancer Med, 2019, 8(6):3269-3277.
[11] 霍云丽, 郭子建.肺癌自身抗体在肿瘤早期诊断和治疗中的临床应用进展[J]. 标记免疫分析与临床, 2019, 26(5):887-891.
[12] 王娜娜, 江楠, 杨晓庆, 等.非小细胞肺癌组织起源分子病理分类及其临床意义[J]. 中国肺癌杂志, 2018, 21(7):41-46.
[13] LIU H, REN G, WANG T, et al. Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition[J]. Carcinogenesis, 2015, 36(4):459-468.
[14] WU T, HU H, ZHANG T, et al. miR-25 promotes cell proliferation, migration, and invasion of non-small-cell lung cancer by targeting the LATS2/YAP signaling pathway[J]. Oxid Med Cell Longev, 2019, 2019:9719723.
[15] KÖNIG K, MEDER L, KRÖGER C, et al. Loss of the keratin cytoskeleton is not sufficient to induce epithelial mesenchymal transition in a novel KRAS driven sporadic lung cancer mouse model[J]. PLoS One, 2013, 8(3):e57996.
[16] YAN J, MA C, GAO Y.MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines[J]. Oncol Rep, 2017, 37(5):3146-3154.
[17] 孙慧, 陈风.anillin肌动蛋白结合蛋白在肿瘤中作用的研究进展[J]. 癌症进展, 2019, 17(7):752-753, 764.
[18] ZHOU K, CHEN J, WU J, et al. Profilin 2 promotes proliferation and metastasis of head and neck cancer cells by regulating PI3K/AKT/_-Catenin signaling pathway[J]. Oncol Res, 2019, 27(9):1079-1088.
[19] 王茜, 李光辉, 郭嘉, 等.miR-199b-5p在头颈癌细胞中的表达及对细胞增殖和侵袭能力的影响[J]. 上海口腔医学, 2018, 27(3):265-269.
[20] CUI X B, ZHANG S M, XU Y X, et al. PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma[J]. J Transl Med, 2016, 14(1):137. |